Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Discontinuation Of Anti-TNF-α Therapy In A Chinese Cohort Of Patients With Rheumatoid Arthritis

Cheng-Tao Yang, C. Kuo, S. Luo, K. Yu
Published 2012 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
The aim of this retrospective study was to examine the predictors of discontinuation of anti-tumor necrosis factor (TNF) therapy due to adverse events in Chinese patients with rheumatoid arthritis (RA). Anti-TNF-related adverse events were recorded and analyzed in 217 consecutive patients with RA followed in our institution from 2003 to 2010. Time to discontinuation of anti-TNF-α therapy was estimated using survival analysis techniques. The anti-TNF agents administered were etanercept in 181 patients and adalimumab in 36 patients. The mean age at diagnosis was 45.2 ± 13.5 years, and mean age at initiation of anti-TNF therapy was 51.8 ± 13.0 years. The mean duration of anti-TNF agent use was 36.0 ± 26.5 months (range, 1.4–87.0; median, 26.4 months). Of the 217 patients, 39 (18.0 %) developed adverse events [etanercept in 34 (18.8 %] and adalimumab in 5 (13.9 %)] during the treatment period (tuberculosis in 5, bacterial infections in 19, virus infection in 7, neuropathy in 3, malignancy in 3, other drug-related events in 1, and appendicitis in 1). In patients with RA, older age (≥55 years) at initiation of anti-TNF therapy [odds ratio (OR), 3.20; 95 % confidence interval (CI), 1.67–6.20; p < 0.001], Cr ≥1.5 mg/dL (OR, 5.72; 95 % CI, 1.17–27.90; p = 0.031), and occurrence of adverse events (OR, 3.82; 95 % CI, 1.75–8.35; p = 0.001) were associated with increased likelihood of discontinuation of anti-TNF treatment. In the present study, a significant proportion (7.8 %, 17/217) of patients with RA discontinued anti-TNF treatment because of adverse events. In the elderly and in patients with renal insufficiency, caution is needed when starting anti-TNF treatment.
This paper references
Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden.
L. Tam (2010)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka (2010)
Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.
F. Tubach (2009)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
F. Arnett (1988)
Mycobacterium tuberculosis in Taiwan.
P. Hsueh (2006)
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
R. Maini (1999)
Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry
J. Markenson (2011)
Serious Infection Following Anti–Tumor Necrosis Factor α Therapy in Patients With Rheumatoid Arthritis: Lessons From Interpreting Data From Observational Studies
W. Dixon (2007)
Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
B. J. Radovits (2009)
Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events
L. Konttinen (2005)
Association of infections and tuberculosis with antitumor necrosis factor alpha therapy
N. Patkar (2008)
[Rheumatoid arthritis].
C. Werning (1983)
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment
T. Levälampi (2008)
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
M. Weinblatt (2003)
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
M. Weinblatt (1999)
Elderly-onset rheumatoid arthritis.
D. van Schaardenburg (1994)
TNF‐α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice
A. Marchesoni (2009)
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
W. Dixon (2006)
The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis.
M. Ornstein (1996)
Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
A. Strangfeld (2009)
The Reason for Discontinuation of the First Tumor Necrosis Factor (TNF) Blocking Agent Does Not Influence the Effect of a Second TNF Blocking Agent in Patients with Rheumatoid Arthritis
M. Blom (2009)
The clinical application of etanercept in Chinese patients with rheumatic diseases
Chung-Tei Chou (2006)
Autoimmune diseases induced by TNF-targeted therapies.
M. Ramos-Casals (2008)
Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment
T. Levälampi (2007)
Second‐Line Antirheumatic Drugs in the Elderly with Rheumatoid Arthritis: A Post Hoc Analysis of Three Controlled Trials
S. Dahl (1990)
Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Sophie Martin Du Pan (2009)
The aging of the immune system.
B. Grubeck‐Loebenstein (2002)
Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.
D. Chen (2009)
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
A. Alonso-Ruiz (2008)
Revised criteria for the classification of rheumatoid arthritis.
F. Arnett (1990)
Changes in immune function with age.
R. Yung (2000)
The pathogenesis of rheumatoid arthritis.
A. Koch (2007)
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
J. Keane (2001)
Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy.
D. Chen (2008)
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.
M. Gardam (2003)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar